vs

Side-by-side financial comparison of MYRIAD GENETICS INC (MYGN) and UiPath, Inc. (PATH). Click either name above to swap in a different company.

UiPath, Inc. is the larger business by last-quarter revenue ($411.1M vs $209.8M, roughly 2.0× MYRIAD GENETICS INC). On growth, UiPath, Inc. posted the faster year-over-year revenue change (15.9% vs -0.4%). Over the past eight quarters, MYRIAD GENETICS INC's revenue compounded faster (1.9% CAGR vs 0.7%).

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

UiPath Inc. is a global software company that develops artificial intelligence (AI) and agentic automation and orchestration software. The company's software enables the building and orchestration of AI agents to automate complex processes and workflows.

MYGN vs PATH — Head-to-Head

Bigger by revenue
PATH
PATH
2.0× larger
PATH
$411.1M
$209.8M
MYGN
Growing faster (revenue YoY)
PATH
PATH
+16.3% gap
PATH
15.9%
-0.4%
MYGN
Faster 2-yr revenue CAGR
MYGN
MYGN
Annualised
MYGN
1.9%
0.7%
PATH

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
MYGN
MYGN
PATH
PATH
Revenue
$209.8M
$411.1M
Net Profit
$198.8M
Gross Margin
70.0%
83.3%
Operating Margin
-2.7%
3.2%
Net Margin
48.4%
Revenue YoY
-0.4%
15.9%
Net Profit YoY
1966.2%
EPS (diluted)
$-0.09
$0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MYGN
MYGN
PATH
PATH
Q4 25
$209.8M
$411.1M
Q3 25
$205.7M
$361.7M
Q2 25
$213.1M
$356.6M
Q1 25
$195.9M
$423.6M
Q4 24
$210.6M
$354.7M
Q3 24
$213.3M
$316.3M
Q2 24
$211.5M
$335.1M
Q1 24
$202.2M
$405.3M
Net Profit
MYGN
MYGN
PATH
PATH
Q4 25
$198.8M
Q3 25
$-27.4M
$1.6M
Q2 25
$-330.5M
$-22.6M
Q1 25
$-100.0K
$51.8M
Q4 24
$-10.7M
Q3 24
$-22.1M
$-86.1M
Q2 24
$-36.7M
$-28.7M
Q1 24
$-26.0M
$33.9M
Gross Margin
MYGN
MYGN
PATH
PATH
Q4 25
70.0%
83.3%
Q3 25
69.9%
82.2%
Q2 25
71.2%
82.1%
Q1 25
68.5%
84.8%
Q4 24
71.7%
82.0%
Q3 24
70.2%
80.0%
Q2 24
69.6%
83.5%
Q1 24
68.1%
86.8%
Operating Margin
MYGN
MYGN
PATH
PATH
Q4 25
-2.7%
3.2%
Q3 25
-11.3%
-5.6%
Q2 25
-154.5%
-4.6%
Q1 25
-14.8%
7.9%
Q4 24
-18.6%
-12.2%
Q3 24
-9.4%
-32.7%
Q2 24
-17.3%
-14.8%
Q1 24
-13.8%
3.7%
Net Margin
MYGN
MYGN
PATH
PATH
Q4 25
48.4%
Q3 25
-13.3%
0.4%
Q2 25
-155.1%
-6.3%
Q1 25
-0.1%
12.2%
Q4 24
-3.0%
Q3 24
-10.4%
-27.2%
Q2 24
-17.4%
-8.6%
Q1 24
-12.9%
8.4%
EPS (diluted)
MYGN
MYGN
PATH
PATH
Q4 25
$-0.09
$0.37
Q3 25
$-0.29
$0.00
Q2 25
$-3.57
$-0.04
Q1 25
$0.00
$0.09
Q4 24
$-0.47
$-0.02
Q3 24
$-0.24
$-0.15
Q2 24
$-0.41
$-0.05
Q1 24
$-0.29
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MYGN
MYGN
PATH
PATH
Cash + ST InvestmentsLiquidity on hand
$149.6M
$1.4B
Total DebtLower is stronger
$119.9M
Stockholders' EquityBook value
$368.0M
$1.9B
Total Assets
$706.6M
$2.9B
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MYGN
MYGN
PATH
PATH
Q4 25
$149.6M
$1.4B
Q3 25
$145.4M
$1.4B
Q2 25
$74.4M
$1.6B
Q1 25
$91.8M
$1.6B
Q4 24
$102.4M
$1.6B
Q3 24
$99.9M
$1.7B
Q2 24
$97.3M
$1.9B
Q1 24
$104.3M
$1.9B
Total Debt
MYGN
MYGN
PATH
PATH
Q4 25
$119.9M
Q3 25
$119.5M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
MYGN
MYGN
PATH
PATH
Q4 25
$368.0M
$1.9B
Q3 25
$372.8M
$1.7B
Q2 25
$388.1M
$1.7B
Q1 25
$704.9M
$1.8B
Q4 24
$701.1M
$1.7B
Q3 24
$731.7M
$1.8B
Q2 24
$740.5M
$2.0B
Q1 24
$760.0M
$2.0B
Total Assets
MYGN
MYGN
PATH
PATH
Q4 25
$706.6M
$2.9B
Q3 25
$728.1M
$2.6B
Q2 25
$677.3M
$2.6B
Q1 25
$1.0B
$2.9B
Q4 24
$1.0B
$2.7B
Q3 24
$1.1B
$2.7B
Q2 24
$1.1B
$2.8B
Q1 24
$1.1B
$3.0B
Debt / Equity
MYGN
MYGN
PATH
PATH
Q4 25
0.33×
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MYGN
MYGN
PATH
PATH
Operating Cash FlowLast quarter
$10.6M
$28.3M
Free Cash FlowOCF − Capex
$25.1M
FCF MarginFCF / Revenue
6.1%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
0.14×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MYGN
MYGN
PATH
PATH
Q4 25
$10.6M
$28.3M
Q3 25
$21.1M
$41.6M
Q2 25
$-13.6M
$119.0M
Q1 25
$-16.3M
$146.1M
Q4 24
$6.6M
$28.1M
Q3 24
$700.0K
$46.4M
Q2 24
$2.6M
$100.0M
Q1 24
$-18.6M
$145.6M
Free Cash Flow
MYGN
MYGN
PATH
PATH
Q4 25
$25.1M
Q3 25
Q2 25
$106.2M
Q1 25
$138.7M
Q4 24
$23.2M
Q3 24
$45.0M
Q2 24
$98.8M
Q1 24
$141.8M
FCF Margin
MYGN
MYGN
PATH
PATH
Q4 25
6.1%
Q3 25
Q2 25
29.8%
Q1 25
32.7%
Q4 24
6.5%
Q3 24
14.2%
Q2 24
29.5%
Q1 24
35.0%
Capex Intensity
MYGN
MYGN
PATH
PATH
Q4 25
0.8%
Q3 25
0.0%
Q2 25
3.6%
Q1 25
1.7%
Q4 24
1.4%
Q3 24
0.4%
Q2 24
0.4%
Q1 24
0.9%
Cash Conversion
MYGN
MYGN
PATH
PATH
Q4 25
0.14×
Q3 25
26.25×
Q2 25
Q1 25
2.82×
Q4 24
Q3 24
Q2 24
Q1 24
4.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MYGN
MYGN

Segment breakdown not available.

PATH
PATH

Subscription Services$247.6M60%
License$150.0M36%
Professional Services And Other$13.5M3%

Related Comparisons